• 1
    Brodowicz T, Ciuleanu T, Crawford J, et al;Central European Cooperative Oncology Group (CECOG). Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. Ann Oncol. 2012;23:1223-1229.
  • 2
    Heon S, Johnson BE. Adjuvant chemotherapy for surgically resected non-small cell lung cancer. J Thorac Cardiovasc Surg. 2012;144:S39-S42.
  • 3
    Chhatwani L, Cabebe E, Wakelee HA. Adjuvant treatment of resected lung cancer. Proc Am Thorac Soc. 2009;6:194-200.
  • 4
    Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995;311:899-909.
  • 5
    Scagliotti GV, Fossati R, Torri V, et al;Adjuvant Lung Project Italy/European Organisation for Research Treatment of Cancer-Lung Cancer Cooperative Group Investigators. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst. 2003;95:1453-1461.
  • 6
    Waller D, Peake MD, Stephens RJ, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg. 2004;26:173-182.
  • 7
    Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351-360.
  • 8
    Winton T, Livingston R, Johnson D, et al;National Cancer Institute of Canada Clinical Trials Group;National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352:2589-2597.
  • 9
    Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7:719-727.
  • 10
    Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552-3559.
  • 11
    Strauss GM, Herndon JE 2nd, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB non-small-cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) Protocol 9633 [abstract]. J Clin Oncol. 2004;22(No.14 suppl). Abstract 7019.
  • 12
    Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633 [abstract]. J Clin Oncol. 2006;24(No.18 suppl). Abstract 7007.
  • 13
    Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(suppl 3):234S-242S.
  • 14
    Ettinger DS, Akerley W, Bepler G, et al;NCCN Non-Small Cell Lung Cancer Panel Members. Non-small cell lung cancer. J Natl Compr Canc Netw. 2010;8:740-801.
  • 15
    Zullig LL, Jackson GL, Dorn RA, et al. Cancer incidence among patients of the U.S. Veterans Affairs Health Care System. Mil Med. 2012;177:693-701.
  • 16
    Greene FL, Page DC, Fleming ID, et al, eds. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002.
  • 17
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
  • 18
    Sohn MW, Arnold N, Maynard C, Hynes DM. Accuracy and completeness of mortality data in the Department of Veterans Affairs. Popul Health Metr. 2006;4:2.
  • 19
    Booth CM, Shepherd FA, Peng Y, et al. Adoption of adjuvant chemotherapy for non-small-cell lung cancer: a population-based outcomes study. J Clin Oncol. 2010;28:3472-3478.
  • 20
    Ryoo JJ, Ordin DL, Antonio AL, et al. Patient preference and contraindications in measuring quality of care: what do administrative data miss? J Clin Oncol. 2013;31:2716-2723.
  • 21
    Kassam F, Shepherd FA, Johnston M, et al. Referral patterns for adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. J Thorac Oncol. 2007;2:39-43.
  • 22
    Massard C, Tran Ba Loc P, Haddad V, et al. Use of adjuvant chemotherapy in non-small cell lung cancer in routine practice. J Thorac Oncol. 2009;4:1504-1510.
  • 23
    Bonomi M, Pilotto S, Milella M, et al. Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research. J Exp Clin Cancer Res. 2011;30:115.
  • 24
    Wang S, Wong ML, Hamilton N, Davoren JB, Jahan TM, Walter LC. Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans. J Clin Oncol. 2012;30:1447-1455.
  • 25
    Patel MI, Wakelee HA. Adjuvant chemotherapy for early stage non-small cell lung cancer. Front Oncol. 2011;1:45.
  • 26
    Gu F, Wisnivesky JP, Mhango G, Strauss GM. Carboplatin versus cisplatin-based adjuvant chemotherapy in elderly patients with stages IB, II, and IIIA non-small cell lung cancer in the community setting [abstract]. J Clin Oncol. 2013;31(No.15 suppl). Abstract 7533.
  • 27
    Felip E, Martinez-Marti A, Martinez P, et al. Adjuvant treatment of resected nonsmall cell lung cancer: state of the art and new potential developments. Curr Opin Oncol. 2013;25:115-120.
  • 28
    National Library of Medicine. Accessed January 20, 2014.
  • 29
    Novello S, Manegold C, Grohe C, et al. International tailored chemotherapy adjuvant trial: Itaca trial [abstract]. J Clin Oncol. 2012;30(No.15 suppl). Abstract TPS7109.